Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 614-406-6 | CAS number: 68308-61-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
GARDO TP10451 is a highly viscous liquid at room temperature with a molecular weight of 1173.4 g/mol (ideally). The melting point/boiling point of the substance could not be determined analytically, as the substance shows a glass transition at -53 °C and decomposes on heating starting at 168 °C. Melting point/boiling point calculation with the EPIWEB 4.0 programme (US EPA 2008) revealed a boiling point of 480.00 °C and a melting point of 90.27 °C. Estimation of the vapour pressure on the base of the calculated MP/BP yielded a vapour pressure of 2.75E-09 Pa at 25 °C (Modified Grain method). The partition coefficient (log Pow = 18.43) was estimated using the EPIWEB 4.0 programme (US EPA 2008). The substance’s water solubility was estimated to be 3.825E-018 mg/l at 25 °C, also with the EPIWEB 4.0 programme (US EPA 2008). As the substance is a liquid with a high molecular weight, vapour pressure was estimated to be extremely low and the substance decomposes upon heating, very little exposure via inhalation (as gas) is expected. Even though the log Pow suggests that some absorption directly across the respiratory tract epithelium can occur, the high molecular weight indicates that the substance will hardly become bioavailable via the inhalation route. Further, the substance showed low toxicity after oral and dermal administration. Together this indicates low systemic availability after inhalation and, if bioavailable, low toxicity via this route of administration. Based on physical-chemical properties GARDO TP10451 absorption across the skin is likely to be low. Due to the substance’s high log POW (higher 6), the rate of transfer between the stratum corneum and the epidermis will be slow and will limit absorption across the skin. Further, uptake into the stratum corneum may itself be low, not only due to the high log POW, but also because the molecular weight is high and water solubility is low. No toxicity, neither local nor systemic, was observed following dermal application of 2000 mg/kg bw (limit dose). Administered orally, GARDO TP10451 is not likely to dissolve in the stomach easily, due to its low water solubility (much lower than 1 mg/L). As only dissolved substance is available for adsorption, the quantity of GARDO TP10451 to become bioavailable via the oral route is low. Further, high molecular weight does not favour passive diffusion across the gastrointestinal tract. Therefore, most likely very low amounts of GARDO TP10451 or breakdown products will become bioavailable. Most of GARDO TP10451 ingested will be eliminated through faeces. Respectively, toxicity to orally administered GARDO TP10451 is low, as shown in acute and subacute toxicity tests (NOAEL = 1000 mg/kg bw/day; limit dose). If bioavailable, GARDO TP10451 is not likely to bioaccumulate. A BCF estimation using the estimated log Pow of 18.43 shows an estimated log BCF of 0.500 with a resulting BCF of 3.162 (EPIWEB 4.0 programme; US EPA 2008).Therefore, bioaccumulation/concentration is not very likely. Low amounts of GARDO TP10451 available systemically are likely to be metabolised and parent compound and degradation products are expected to distribute via systemic circulation. Metabolism may transform GARDO TP10451 into more polar degradation products. Likely pathways are reactions such as cleavage at the ester side-chains by esterases and ß-oxidation, which mediates the chain degradation of the fatty acids. Parent compound and metabolites formed in metabolic reactions may be rendered more polar by further metabolic activity in subsequent reactions. The parent compound or possible metabolites may undergo conjugation (e.g. with glutathione), before being excreted in urine or bile. In the absence of any clinical pathology alterations in the long-term studies, no adverse effects are assumed. It is unlikely that GARDO TP10451 is metabolised to more reactive (toxic) products. This assumption is supported by results obtained in oral and dermal toxicity studies and three in vitro tests (Reverse Mutation Assay using Bacteria (Ames-Test),In vitroMammalian Chromosome Aberration Test in Chinese Hamster V79 cells,In vitroMammalian Cell Gene Mutation Test – Mouse Lymphoma Assay). In acute and subacute in vivo studies toxicity was low. In an Ames test and a chromosome aberration assay no significant increase in toxicity was noted in the presence of a rodent microsomal S9-fraction, when compared to incubation without S9-fraction. Together, this data indicates that formation of reactive metabolites is rather unlikely. Based on the substance’s structure and associated physical-chemical characteristics, very low to low amounts of GARDO TP10451 will become bioavailable through inhalation, upon contact to skin or following oral ingestion. When bioavailable, the substance or its metabolites are expected to distribute, with excretion via urine or bile (polar conjugated forms, breakdown products) and via faces (high molecular weight forms, unchanged substance). Bioaccumulation is unlikely.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.